Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 3.45 0.00 07:45:19
Bid Price Offer Price High Price Low Price Open Price
3.40 3.50 3.45 3.45 3.45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.17 -0.99 9
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 3.45 GBX

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Investors    Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date Time Title Posts
31/3/202209:20Evgen Pharma: Undoubted Transformational Upside Potential2,432
02/9/202110:06Evgen Guild thread149

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 3.45p.
Evgen Pharma Plc has a 4 week average price of 3.35p and a 12 week average price of 3.35p.
The 1 year high share price is 8.28p while the 1 year low share price is currently 3.08p.
There are currently 274,888,117 shares in issue and the average daily traded volume is 225,280 shares. The market capitalisation of Evgen Pharma Plc is £9,483,640.04.
manual dexterity: Evgen Pharma PLC Collaboration with University of Michigan RNS Number : 5593O Evgen Pharma PLC 13 June 2022 Evgen Pharma plc ("Evgen" or the "Company") Collaboration with University of Michigan to evaluate SFX-01 in models of colorectal cancer Alderley Park, UK - 13 June 2022 : Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines for the treatment of cancer and other indications , announces a collaboration with Dr Grace Chen, of the University of Michigan, to investigate the potential anti-tumour effects of the Company's lead asset, SFX-01 in colorectal cancer. SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Previous studies of the compound have shown in vivo and in vitro efficacy of the compound in a wide range of cancer cells including breast cancer, glioblastoma and certain blood cancers. The collaboration with the University of Michigan seeks to evaluate the in vivo effects of SFX-01 in models of colorectal cancer. The effects and mechanism of action of SFX-01 on organoid growth, morphology, stemness and inflammatory markers will also be investigated, using normal and malignant patient-derived organoids and tumour tissue. Initial results are expected at the end of 2023. Colorectal cancer is considered to be the third most common form of cancer worldwide, with between 1.5-2 million annual diagnoses, and second leading cause of cancer-related deaths. There has also been an alarming global rise in early-onset colorectal cancer occurring in individuals under 50 years of age. Treating colorectal cancers can be difficult and does not always lead to cure especially in advanced stages. Therefore, there is a strong need to develop chemoprevention strategies as well as better treatment options. Dr Huw Jones, Evgen CEO, commented: "This new project is our fifteenth pre-clinical collaboration to date. Colorectal cancer is a relatively common disease and a cancer type we have not explored extensively. The work of Dr. Chen's group will gain valuable insights into the effects of SFX-01 in models of colorectal cancer. Building on our existing promising data on the mode of action, efficacy and tolerability of our lead asset, we continue to develop our core products to address the widest possible range of indications." Dr Grace Chen, of the University of Michigan, lead investigator, commented: "We have seen the encouraging data of SFX-01 in various indications and want to understand more about the potential of Evgen's sulforaphane-synthetising technology in colorectal cancer to help develop prevention strategies especially in high-risk patients and improved treatment options for patients with advanced colorectal cancer." Evgen's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. Sulforaphanes have shown potential benefits in oncology by reducing inflammation and blocking DNA mutation of cancer. -Ends-
manual dexterity: Those early sells now being taken up. I do think a lot of the groundwork has been done so lets see what transpires. Morning Note from Finncap with an 18p target. EVGEN PHARMA (EVG): CORP Full-year results: SFX-01 clinical focus for the year ahead Evgen reported full-year results to end March 2022 with a pre-tax loss of £3.1m slightly better than our forecast loss of £3.3m. As a result, net cash and short-term investments were also higher at £9m vs £7.6m. The Group made good pre-clinical progress on several fronts during the year on lead asset SFX-01 including in cdk4/6 resistant breast cancer, glioblastoma (including US FDA Orphan Drug Designation), Juvenile Myelomonocytic Leukaemia, scale up of manufacturing and formulation improvements. As the Group prepares to initiate two clinical studies in the coming year with a new SFX-01 formulation (phase I/Ib) and in glioblastoma multiforme (phase Ib/IIa), R&D spend will increase in the coming twelve months. However, we estimate that the Group has a cash runway until end-2023 before expected milestone payments from the JuvLife collaboration begin to defray the operating costs and this forecast does not include any income from potential business development activities. We make changes to our forecasts as outlined later in our full note, but our DCF-derived target price of 18p is unchanged.
manual dexterity: Juvenescence alone is up to $10million on licensing fees and more. Due next year but tomorrow may also give more information as to upcoming trials. EVG has been decimated in terms of share price but it is in a far better position that most.
manual dexterity: As with MTPH, EVG has hit rock bottom in terms of the share price. One bit of good news with MTPH and its up 50%. EVG is due news on several fronts. Phase I study of biomarkers: Design of this trial is almost complete and a dialogue with the MHRA has commenced. The intention is to start the trial in Q2 next year as soon as the new tablet formulation of SFX-01 has been finalised and manufactured in sufficient quantities. Metastatic breast cancer : This would be designed as a Phase II placebo-controlled study and most likely would be conducted in partnership. Glioblastoma : We are now at a late stage in designing a Phase Ib/II clinical study and liaising with potential trial sites in the UK and across Europe. The trial could commence in Q2 2022. There is lots of news to come:
manual dexterity: Any one of those news indicated in this quarter will do very well for the share price. We need that news but as the share price is at near all time lows and funding adequate I think EVG is worth another look. Peterm has spot on, on cancer trials.
manual dexterity: !FOLLOWFEED UPDATE PRESENTATION Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Pipeline Recent Achievements mBC Commencement of pre-clinical collaboration with the University of Manchester and The Christie Hospital. Generate data to optimise positioning of SFX-01 in breast cancer treatment following promising Phase 2a clinical data.Out license market average $19m up front, $144m total, 10-14% royalty* Glioma Publication of powerful pre-clinical data including significant survival benefit, October 2021.Out licence market average $11m up front, $90m total, 8-12% royalty* Onc 3 Collaboration underway with a prestigious academic institution on a target relevant to solid tumours and blood cancers. Partner Sulforadex technology licence concluded with Juvenescence for nonpharmaceutical applications using naturally derived sulforaphane. $10.5m in milestones / options plus royalty. Market launch in 2023 FDA Orphan Drug designation achieved with FDA for malignant gliom. Cash Trajectory to last till 2024.
manual dexterity: New thread for discussion on Evgen Pharam. I will be updating the thread over today. The share price has fallen from placing price of 8p to 3.5p. Adequate cash to last 2-3 years and an updated website and presentation. Drugs in development include SFX-01 and others.
moneymunch: RNS Number : 7343Y Evgen Pharma PLC 18 January 2022 Evgen Pharma plc ("Evgen" or "the Company") Option over new sulforaphane analogues Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces a Memorandum of Understanding with the University of Seville ('US'), Consejo Superior de Investigaciones Científicas ('CSIC') and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville, for second generation sulforaphane analogues. Under the agreement Evgen has signed an exclusive option to license new, novel sulforaphane analogues synthesised by these Spanish institutions, subject to a fixed evaluation period. These analogues have the potential for differentiation from SFX-01 in terms of product formulation. They may also have the potential for differential activity against targets that Evgen is pursuing such as STAT3, SHP2 and Nrf2. As such, they could constitute follow-on and/or alternative products which would expand Evgen's development and partnering opportunities. If the option is exercised it would expand substantially Evgen's preclinical pipeline of sulforaphane analogues. Analogues from an existing license from US and CSIC are currently undergoing further screening against relevant targets. The current option will be exercised should the Company's technical evaluation be positive. Dr Huw Jones, Chief Executive Officer of Evgen Pharma, said: "I am delighted that we are extending our collaboration with the CSIC and University of Seville, and the opportunity this gives us to broaden our sulforaphane-based drug pipeline. If differentiation is demonstrated in the laboratory, we then have considerable potential to target diseases where one of the key molecular targets for sulforaphane is more relevant than others, enhancing our pipeline substantially."
moneymunch: RNS Number : 9875X Evgen Pharma PLC 11 January 2022 Evgen Pharma plc ("Evgen" or "the Company" or "the Group") Progress with UK and US regulators for 2022 clinical trials Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) in relation to two clinical trials set to commence in 2022. The first trial is a Phase I human volunteer study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of Evgen's new SFX-01 tablet formulation. In addition, the study, which will recruit volunteers randomised to active and placebo arms, will generate data on dose escalation and target pathway engagement. Evgen held a scientific advice meeting with the MHRA in December 2021 at which the draft trial protocol was discussed and the MHRA's written advice, which will reflect the discussions on the data to be submitted in support of approval of the trial, is expected in late January. Separately, and also in accordance with time lines set out in Q1 2021, Evgen submitted an application for a pre-IND (Investigational New Drug application) meeting to the FDA in December 2021. This request has now been granted, to be effected by written responses to a meeting package that will be submitted to FDA in January. The IND will relate to a Phase Ib/II trial of SFX-01 in glioblastoma that is planned to commence in 2022 and Evgen is liaising with potential trial sites in the UK and Europe. The trial design will be adaptive to enable extension towards a registration if the data are supportive of this. In these circumstances trial sites in the US are likely to be involved. Part of the proceeds from the 2021 placing and open offer have been applied to improve the synthesis and formulation of SFX-01 for commercial scale. This new tablet formulation will be used in all clinical trials; the production process has started and Evgen anticipates drug product will be available for commencement of the Phase I human volunteer study in Q2 this year. Dr Huw Jones, Chief Executive Officer of Evgen Pharma, said: "I am delighted with the positive progress that has been made with MHRA and FDA regarding our two planned clinical trials for SFX-01, both of which we intend to commence later this year. We look forward to updating the market in due course regarding further progress with these key regulatory authorities and with regard to these two important trials."
diamondstar1: Despite some of my negativity with regards to the STAR Trial, I believe that ex-CEO Stephen Franklin’s initiative to get the trial started with Prof. Chalmers was simply BRILLIANT. Why? Because so much free money was available for COVID research, it was simply another opportunity to raise the profile of Evgen. This has allowed Evgen to raise a further round of funding at a higher share price, and attract institutional investors. Without the STAR Trial and interest in COVID - my feeling is that share price would dropped further - and they would have had to raise funding at much lower valuations. So, at least current share price is underpinned by cash in hand circa £10 million. But think about this guys - why have they now failed on 2 occasions in getting a positive trial result ie for SAH and now ARDS? They are not selecting their disease targets properly! Why is US-based Reata Pharmaceuticals - founded in 2002 (with their lead product Bardoloxone - a NRF2 upregulator) - worth $5 billion in market cap? Why is Evgen Pharma - founded in 2007 - with NRF2 activator SFX-01 - only valued at £13 million?
Evgen Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220701 11:38:48